Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...
How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...
3d
Shuffle like an Egyptian: Columbia tattoo artist releasing tarot-esque deck full of myth, mysticism
The 40-card oracle deck was born out of the relationship the illustrator and writer formed while on a trip to Egypt. We took ...
21hon MSN
Oracle's $553 billion backlog is either a gold mine or a mirage. Earnings just revealed the answer
Oracle ended its fiscal third quarter with $553 billion in remaining purchase obligations -- up 325% year over year.
Oracle Fin Serv Standalone December 2025 Net Sales at Rs 1,452.70 crore, up 11.28% Y-o-Y Jan 22 2026 01:19 PM Oracle Fin Serv Standalone December 2025 Net Sales at Rs 1,452.70 crore, up 11.28% Y-o-Y ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results